APA (7th ed.) Citation

U, K., BK, P., TJ, M., DVV, K., & SS, C. (2024). Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far. Clinical drug investigation, 44(4), 223. https://doi.org/10.1007/s40261-024-01351-5

Chicago Style (17th ed.) Citation

U, Kaur, Pathak BK, Meerashahib TJ, Krishna DVV, and Chakrabarti SS. "Should Glucokinase Be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far." Clinical Drug Investigation 44, no. 4 (2024): 223. https://doi.org/10.1007/s40261-024-01351-5.

MLA (9th ed.) Citation

U, Kaur, et al. "Should Glucokinase Be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far." Clinical Drug Investigation, vol. 44, no. 4, 2024, p. 223, https://doi.org/10.1007/s40261-024-01351-5.